Lleo A, Wang GQ, Gershwin ME, et al. Primary biliary cholangitis. Lancet. 2020;396:1915–26.

Article  CAS  PubMed  Google Scholar 

European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–72.

Article  Google Scholar 

Lindor KD, Bowlus CL, Boyer J, et al. primary biliary cholangitis: 2018 practice guidance from the American Association for the study of liver diseases. Hepatology. 2019;69:394–419.

Article  PubMed  Google Scholar 

Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019;114:48–63.

Article  PubMed  Google Scholar 

Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020;17:93–110.

Article  PubMed  Google Scholar 

Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297–303.

Article  CAS  PubMed  Google Scholar 

Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71:357–65.

Article  CAS  PubMed  Google Scholar 

Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol. 2020;5:306–15.

Article  PubMed  Google Scholar 

Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–20.

Article  PubMed  Google Scholar 

Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–7.

Article  CAS  PubMed  Google Scholar 

Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281–7.

Article  CAS  PubMed  Google Scholar 

Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186–94.

Article  CAS  PubMed  Google Scholar 

Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361–7.

Article  CAS  PubMed  Google Scholar 

Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149:1804-1812.e4.

Article  PubMed  Google Scholar 

Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63:930–50.

Article  CAS  PubMed  Google Scholar 

Carbone M, Nardi A, Flack S, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol. 2018;3:626–34.

Article  PubMed  PubMed Central  Google Scholar 

Yang C, Guo G, Li B, et al. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatol Int. 2023;17:237–48.

Article  PubMed  Google Scholar 

Shuai Z, Wang J, Badamagunta M, et al. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology. 2017;65:1670–82.

Article  CAS  PubMed  Google Scholar 

Tanaka T, Zhang W, Sun Y, et al. Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics. Hepatology. 2017;66:885–95.

Article  CAS  PubMed  Google Scholar 

Tanaka A, Leung PSC, Gershwin ME. The genetics and epigenetics of primary biliary cholangitis. Clin Liver Dis. 2018;22:443–55.

Article  PubMed  Google Scholar 

Cordell HJ, Fryett JJ, Ueno K, et al. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. J Hepatol. 2021;75:572–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.

Article  Google Scholar 

Chen L, Ge B, Casale FP, et al. Genetic drivers of epigenetic and transcriptional variation in human immune cells. Cell. 2016;167:1398-1414.e24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580–5.

Article  Google Scholar 

Phan L, Jin Y, Zhang H, Qiang W, et al. ALFA: allele frequency aggregator. USA: National Center for Biotechnology Information, U.S. National Library of Medicine; 2020.

Google Scholar 

Burré J, Zimmermann H, Volknandt W. Identification and characterization of SV31, a novel synaptic vesicle membrane protein and potential transporter. J Neurochem. 2007;103:276–87.

Article  PubMed  Google Scholar 

Sanchez VB, Ali S, Escobar A, et al. Transmembrane 163 (TMEM163) protein effluxes zinc. Arch Biochem Biophys. 2019;677: 108166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tabassum R, Chauhan G, Dwivedi OP, et al. Genome-wide association study for type 2 diabetes in Indians identifies a new susceptibility locus at 2q21. Diabetes. 2013;62:977–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014;46:989–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091–102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chakraborty S, Vellarikkal SK, Sivasubbu S, et al. Role of Tmem163 in zinc-regulated insulin storage of MIN6 cells: Functional exploration of an Indian type 2 diabetes GWAS associated gene. Biochem Biophys Res Commun. 2020;522:1022–9.

Article  CAS  PubMed  Google Scholar 

Salm EJ, Dunn PJ, Shan L, et al. TMEM163 regulates ATP-gated P2X receptor and behavior. Cell Rep. 2020;31: 107704.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan Y, Liu T, Huang X, et al. A zinc transporter, transmembrane protein 163, is critical for the biogenesis of platelet dense granules. Blood. 2021;137:1804–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonaventura P, Benedetti G, Albarède F, et al. Zinc and its role in immunity and inflammation. Autoimmun Rev. 2015;14:277–85.

Article  CAS  PubMed  Google Scholar 

Kambe T, Tsuji T, Hashimoto A, et al. The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism. Physiol Rev. 2015;95:749–84.

Article  CAS  PubMed  Google Scholar 

Goel A, Kim WR. Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems. Clin Liver Dis. 2018;22:563–78.

Article  PubMed  Google Scholar 

Efe C, Taşçilar K, Henriksson I, et al. Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis. Am J Gastroenterol. 2019;114:1101–8.

Article  PubMed  Google Scholar 

Cheung KS, Seto WK, Fung J, et al. Prognostic factors for transplant-free survival and validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid. Clin Transl Gastroenterol. 2017;8: e100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang F, Yang Y, Wang Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther. 2017;45:733–43.

Article  CAS